Literature DB >> 28870960

Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.

Enzo Ricciardi1, Federica Tomao2, Giovanni Aletti2, Luca Bazzurini2, Luca Bocciolone2, Sara Boveri2, Fabio Landoni2, Maria Teresa Lapresa2, Matteo Maruccio2, Gabriella Parma2, Fedro Peccatori2, Maria Cristina Petrella2, Vanna Zanagnolo2, Nicoletta Colombo2, Angelo Maggioni2.   

Abstract

BACKGROUND/AIM: Occult cancers' reported rates vary from 2-12% and serous tubal intraepithelial carcinomas (STICs) have been identified in 3-12% of the prophylactically removed tubes of women carrying a BRCA mutation. The aim of this study was to evaluate the incidence of tubal minor epithelial atypia (STIL), STIC, and occult invasive cancer and to evaluate the cancer-specific mortality in a prospective series of women at higher risk of ovarian and breast cancer undergoing risk-reducing salpingo-oophorectomy (RRSO) n a tertiary cancer center. PATIENTS AND METHODS: A series of RRSO specimens (including endometrial biopsy) from women carrying a BRCA mutation, BRCA-unknown and BRCA-negative were collected between January 1998 and April 2016 at the Division of Gynecology at the European Institute of Oncology. Inclusion criteria were: asymptomatic women who had a negative gynecologic screening within 3 months prior to RRSO. Exclusion criteria were: women with ovarian/tubal cancer prior to RRSO.
RESULTS: A total of 411 women underwent RRSO. Median age at RRSO was 47.0 years (range=32-70 years); 75.2% had a history of breast cancer. Fifteen women were diagnosed with an occult cancer (7 STIC, 4 invasive cancers, 2 breast cancers metastatic to the adnexa, 2 endometrial cancer) (3.6%). Sixteen showed a STIL (3.9%). When excluding cases with preoperative positive markers, the occult invasive cancer rate drops to 1.5%.
CONCLUSION: Our study, covering an 18-year period, shows a substantial low risk of occult cancer among a high-risk population of women undergoing RRSO. Our data still support the indication for RRSO in higher-risk patients. An endometrial biopsy should also be routinely obtained as it raises the chances of detecting occult endometrial cancers that may be otherwise missed. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BRCA genes; Risk-reducing salpingo-oophorectomy; STIC; breast cancer; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28870960     DOI: 10.21873/anticanres.11948

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Recommendations for diagnosing STIC: a systematic review and meta-analysis.

Authors:  Joep M A Bogaerts; Miranda P Steenbeek; Majke H D van Bommel; Johan Bulten; Jeroen A W M van der Laak; Joanne A de Hullu; Michiel Simons
Journal:  Virchows Arch       Date:  2021-12-01       Impact factor: 4.535

2.  Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.

Authors:  Valerie Catherine Linz; Amelie Löwe; Josche van der Ven; Annette Hasenburg; Marco Johannes Battista
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

3.  Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.

Authors:  Guojiao Lu; Tao Lu; Jichen Pan; Ling Guo; Yingxin Pang; Peishu Liu
Journal:  Arch Gynecol Obstet       Date:  2020-11-20       Impact factor: 2.344

4.  An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.

Authors:  Lučka Boltežar; Gorana Gašljević; Srdjan Novaković; Vida Stegel; Erik Škof
Journal:  Hered Cancer Clin Pract       Date:  2020-03-19       Impact factor: 2.857

5.  The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.

Authors:  Andreja Gornjec; Sebastijan Merlo; Srdjan Novakovic; Vida Stegel; Barbara Gazic; Andraz Perhavec; Ana Blatnik; Mateja Krajc
Journal:  Radiol Oncol       Date:  2020-05-28       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.